Biological E Limited (BE) announced that the CDSCO approved the Phase 3 infants clinical trial data and recommended for manufacture of its 14-valent paediatric vaccine against Streptococcus pneumoniae infection in single-dose and multidose presentations.
Hyderabad: The city has continued to retain its status as the vaccine capital of the country with yet another top-pharmaceutical company Biological E Limited preparing the ground for the launch of its Covid vaccine ‘Corbevax’ in the next few weeks. The Corbevax has successfully completed its second and third phase of clinical trials and the […]
Hyderabad vaccine maker to purchase CpG 1018 adjuvant from Dynavax for use in the commercial production of Biological E’s Covid-19 vaccine candidate Corbevax
Hyderabad-based firm to run pivotal trial in India and seek emergency use authorisation, and target to reach one billion dose production capacity in 2022
The phase III clinical study to be conducted in 15 sites across India will evaluate the immunogenicity and safety of the SARS-CoV-2 Covid-19 vaccine for protection against the disease
